Human insulin analogs with rapid onset and short duration of action

Peptides ◽  
1992 ◽  
pp. 88-90 ◽  
Author(s):  
H. B. Long ◽  
J. C. Baker ◽  
R. M. Belagaje ◽  
R. D. DiMarchi ◽  
B. H. Frank ◽  
...  
1999 ◽  
Vol 91 (5) ◽  
pp. 1311-1311 ◽  
Author(s):  
Neal W. Fleming ◽  
Frances Chung ◽  
Peter S. A. Glass ◽  
John B. Kitts ◽  
Hans Kirkegaard-Nielsen ◽  
...  

Background Currently, the only approved muscle relaxant with a rapid onset and short duration of action is succinylcholine, a drug with some undesirable effects. Rapacuronium is an investigational nondepolarizing relaxant that also has a rapid onset and short duration and consequently should be compared with succinylcholine in its ability to facilitate rapid tracheal intubation. Methods This prospective, randomized clinical trial involved 336 patients. Anesthesia was induced with fentanyl and propofol and either 1.5 mg/kg rapacuronium or 1.0 mg/kg succinylcholine. The goal was to accomplish tracheal intubation by 60 s after administration of the neuromuscular blocking drug. Endotracheal intubation was performed, and conditions were graded by a blinded investigator. Recovery of neuromuscular function was assessed by electromyography. Results Intubation conditions were evaluated in 236 patients. Intubation by 60 s after drug administration occurred in 100% of patients with rapacuronium and in 98% with succinylcholine. Intubation conditions were excellent or good in 87% of patients with rapacuronium and in 95% with succinylcholine (P < 0.05). The time (median and range) to the first recovery of the train-of-four response was 8.0 (2.8-20.0) min with rapacuronium and 5.7 (1.8-17.7) min with succinylcholine (P < 0.05). The overall incidence of adverse effects was similar with both drugs. Conclusions A 1.5-mg/kg dose of rapacuronium effectively facilitates rapid tracheal intubation. It can be considered a valid alternative to 1.0 mg/kg succinylcholine for this purpose.


1986 ◽  
Vol 24 (13) ◽  
pp. 51-52

Alfentanil (Rapifen - Janssen) is an intravenous opioid analgesic with a rapid onset and short duration of action. It is recommended for use as a bolus injection during short general anaesthesia or by infusion during longer procedures.1,2


2021 ◽  
Vol 534 ◽  
pp. 988-994
Author(s):  
Tomohisa Mori ◽  
Yoshinori Takemura ◽  
Takamichi Arima ◽  
Yoshiyuki Iwase ◽  
Michiko Narita ◽  
...  
Keyword(s):  

2021 ◽  
Author(s):  
Wakako Mori ◽  
Keisuke Yuzu ◽  
Nadine Lobsiger ◽  
Hideo Nishioka ◽  
Hisako Sato ◽  
...  

Abstract Insulin balls, localized insulin amyloids formed at subcutaneous insulin-injection sites in patients with diabetes, cause poor glycemic control owing to impairments in insulin absorption. Our previous study has shown that some insulin balls are cytotoxic, but others are not, implying amyloid polymorphism. Interestingly, the patient with toxic insulin balls had been treated with antibiotic minocycline, suggesting a possible relationship between toxicity of insulin balls and minocycline. However, the direct effect of minocycline on the structure and cytotoxicity of the insulin amyloid is still unclear. Herein, we demonstrated that that minocycline at physiological concentrations induced degradation of insulin amyloids formed from human insulin and insulin drug preparations used for diabetes patients. Interestingly, the process involved the initial appearance of the toxic species, which subsequently changed into less-toxic species. It is also shown that the structure of the toxic species was similar to that of sonicated fragments of human insulin amyloids. Our study shed new light on the clarification of the revelation of insulin balls and the development of the insulin analogs for diabetes therapy.


2021 ◽  
Vol 18 (2) ◽  
pp. 66-76
Author(s):  
Alexander V. Emelyanov ◽  
Galina R. Sergeeva ◽  
Evgenia V. Leshenkova

The second generation of H1-antihistamines is approved for the stepwise treatment of seasonal and perennial allergic rhinitis in adults and children by international and national guidelines. They reduce the severity of nasal and ocular symptoms of rhinitis and improve the quality of life of patients. Bilastine, a piperidine derivative, is a novel H1-antihistamine. It has a potent and selective effect on H1- receptors and a rapid onset and long duration of action and substantially reduces nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Bilastine has no clinically substantial hepatic metabolism and has a high safety profile: it has no sedative effect, does not affect cognitive functions, has no cardiotoxic effects, and does not interact with alcohol and benzodiazepines in normal and high doses. Tachyphylaxis does not develop despite long-term (up to 1 year) use. Bilastine is registered for clinical use in adults and children aged 12 years. The results of clinical and experimental studies have demonstrated that bilastine has many of the features of modern H1-antihistamines recommended by international guidelines.


Diabetes Care ◽  
2019 ◽  
Vol 43 (2) ◽  
pp. 494-496 ◽  
Author(s):  
Tamara Turk Wensveen ◽  
Dora Fučkar Čupić ◽  
Dubravka Jurišić Eržen ◽  
Bojan Polić ◽  
Felix M. Wensveen

1997 ◽  
Vol 84 (5) ◽  
pp. 1011-1018 ◽  
Author(s):  
Raymond Kahwaji ◽  
David R. Bevan ◽  
George Bikhazi ◽  
Colin A. Shanks ◽  
Robert J. Fragen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document